MA38523A1 - Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma - Google Patents

Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma

Info

Publication number
MA38523A1
MA38523A1 MA38523A MA38523A MA38523A1 MA 38523 A1 MA38523 A1 MA 38523A1 MA 38523 A MA38523 A MA 38523A MA 38523 A MA38523 A MA 38523A MA 38523 A1 MA38523 A1 MA 38523A1
Authority
MA
Morocco
Prior art keywords
ligands
triazole compounds
compounds used
sigma receptors
tricyclic triazole
Prior art date
Application number
MA38523A
Other languages
English (en)
Inventor
José-Luis Diaz-Fernández
Carmen Almansa-Rosales
Félix Cuevas-Cordobés
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA38523A1 publication Critical patent/MA38523A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne de nouveaux composés triazoliques tricycliques de formule (i) présentant une grande affinité pour les récepteurs sigma, en particulier les récepteurs sigma-1, ainsi que le processus pour leur préparation, des compositions les comprenant et leur utilisation comme médicaments pour le traitement par exemple de maladies liées à la douleur.
MA38523A 2013-04-19 2014-04-21 Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma MA38523A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382143.9A EP2792679A1 (fr) 2013-04-19 2013-04-19 Composants triazoliques tricycliques
PCT/EP2014/058036 WO2014170494A1 (fr) 2013-04-19 2014-04-21 Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma

Publications (1)

Publication Number Publication Date
MA38523A1 true MA38523A1 (fr) 2017-03-31

Family

ID=48190443

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38523A MA38523A1 (fr) 2013-04-19 2014-04-21 Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma

Country Status (32)

Country Link
US (1) US9512142B2 (fr)
EP (2) EP2792679A1 (fr)
JP (1) JP6337092B2 (fr)
KR (1) KR102242405B1 (fr)
CN (1) CN106029671B (fr)
AR (1) AR095868A1 (fr)
AU (1) AU2014255679B2 (fr)
BR (1) BR112015026514B1 (fr)
CA (1) CA2909735C (fr)
CY (1) CY1119712T1 (fr)
DK (1) DK2986616T3 (fr)
ES (1) ES2628818T3 (fr)
HK (1) HK1221226A1 (fr)
HR (1) HRP20170949T1 (fr)
HU (1) HUE034797T2 (fr)
IL (1) IL242096B (fr)
LT (1) LT2986616T (fr)
MA (1) MA38523A1 (fr)
MX (1) MX362403B (fr)
MY (1) MY194093A (fr)
PH (1) PH12015502407B1 (fr)
PL (1) PL2986616T3 (fr)
PT (1) PT2986616T (fr)
RS (1) RS56114B1 (fr)
RU (1) RU2666728C2 (fr)
SG (1) SG11201508610QA (fr)
SI (1) SI2986616T1 (fr)
TN (1) TN2015000470A1 (fr)
TW (1) TWI601733B (fr)
UA (1) UA116015C2 (fr)
WO (1) WO2014170494A1 (fr)
ZA (1) ZA201507775B (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000064893A (ko) * 1996-07-20 2000-11-06 클래스 하인츠-게르트 트리아졸로퓨린,이의제조방법및이를함유하는약제학적제제
AU2003245380A1 (en) * 2002-05-30 2003-12-19 King Pharmaceuticals Research & Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
EP1634873A1 (fr) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Inhibiteurs des récepteurs sigma
PE20060653A1 (es) * 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1
EP1829869A1 (fr) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Dérivés de 4,5,6,7-tétrahydrobenzo[b]thiophène et leur utilisaton comme ligands du récepteur sigma
EP1847542A1 (fr) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Dérivés de spiro[benzopyran] ou de spiro[benzofuran] comme antagonistes du récepteur sigma
EP1849772A1 (fr) * 2006-04-28 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Dérivés bicyclic de Tetrahydopyrrole
EP1921071A1 (fr) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3-Triazoles en tant qu'inhibiteurs du récepteur sigma
EP2070933A1 (fr) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Composants triazoliques tricycliques
US20110201599A1 (en) 2008-07-03 2011-08-18 Exelixis, Inc. CDK Modulators

Also Published As

Publication number Publication date
TWI601733B (zh) 2017-10-11
CA2909735A1 (fr) 2014-10-23
HK1221226A1 (zh) 2017-05-26
EP2986616B1 (fr) 2017-03-29
PL2986616T3 (pl) 2017-10-31
CN106029671A (zh) 2016-10-12
UA116015C2 (uk) 2018-01-25
MY194093A (en) 2022-11-11
AU2014255679B2 (en) 2018-07-05
EP2986616A1 (fr) 2016-02-24
HUE034797T2 (en) 2018-02-28
RU2015144720A (ru) 2017-05-24
NZ713391A (en) 2020-11-27
AR095868A1 (es) 2015-11-18
SI2986616T1 (sl) 2017-09-29
IL242096B (en) 2019-05-30
JP2016516799A (ja) 2016-06-09
US9512142B2 (en) 2016-12-06
TN2015000470A1 (en) 2017-04-06
ZA201507775B (en) 2017-09-27
HRP20170949T1 (hr) 2017-09-22
PH12015502407A1 (en) 2016-02-22
SG11201508610QA (en) 2015-11-27
WO2014170494A1 (fr) 2014-10-23
RS56114B1 (sr) 2017-10-31
CN106029671B (zh) 2018-10-12
LT2986616T (lt) 2017-07-10
KR102242405B1 (ko) 2021-04-21
EP2792679A1 (fr) 2014-10-22
DK2986616T3 (da) 2017-06-19
BR112015026514A2 (pt) 2017-07-25
US20160060275A1 (en) 2016-03-03
CY1119712T1 (el) 2018-06-27
BR112015026514B1 (pt) 2022-09-13
MX362403B (es) 2019-01-15
AU2014255679A1 (en) 2015-11-05
PH12015502407B1 (en) 2016-02-22
RU2666728C2 (ru) 2018-09-12
CA2909735C (fr) 2022-10-04
KR20160025495A (ko) 2016-03-08
ES2628818T3 (es) 2017-08-04
MX2015014516A (es) 2016-02-09
TW201441232A (zh) 2014-11-01
JP6337092B2 (ja) 2018-06-06
PT2986616T (pt) 2017-06-22

Similar Documents

Publication Publication Date Title
MA49809A1 (fr) Composés utilisés comme inhibiteurs de kinase
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA35444B1 (fr) Ligands du récepteur ep1
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA38284A1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA39145B1 (fr) Dérivés de pipérazine ayant une activité multimode contre la douleur
MA38925A1 (fr) Dérivés de phénylalanine substitués
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA42988B1 (fr) Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.
MA39190A1 (fr) Dérivés d'imidazolyle fusionnés, leur préparation et leur utilisation en tant que médicaments
MA38523A1 (fr) Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma
MA42871B1 (fr) Composés utilisés comme inhibiteurs de la tyrosine kinase de bruton (btk)
MA38473B1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c
MA44144B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA43263B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA35894B1 (fr) Composés d'oxazolidine-2-one et utilisations de ceux-ci en tant qu'inhibiteurs des pi3k